SAN DIEGO, March 2, 2016 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Cowen
& Company 36th Annual Healthcare Conference in
Boston on Wednesday, March 9 at 8:40
a.m. ET/5:40 a.m. PT.
On Tuesday, March 15, Halozyme will
also present at the Barclays Capital Global Healthcare Conference
in Miami at 3:50 p.m. ET/12:50 p.m.
PT. Laurie Stelzer,
senior vice president and chief financial officer, will provide a
corporate overview at both conferences.
The presentations will be webcast through the "Investors"
section of www.halozyme.com, and a recording will be made available
for 90 days following each event. To access the live webcast,
please visit Halozyme's website approximately 15 minutes prior to
the presentation to register and download any necessary audio
software.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor in animal models. PEGPH20 is currently in development for
metastatic pancreatic cancer, non-small cell lung cancer, gastric
cancer, metastatic breast cancer and has potential across
additional cancers in combination with different types of cancer
therapies. In addition to its proprietary product portfolio,
Halozyme has established value-driving partnerships with leading
pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme
is headquartered in San Diego. For
more information visit www.halozyme.com.
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-upcoming-healthcare-conferences-300229749.html
SOURCE Halozyme Therapeutics, Inc.